Immunotherapy toxicity: identification and management

O. Gumusay1 · J. Callan1 · H. S. Rugo1

Received: 10 June 2021 / Accepted: 3 December 2021 / Published online: 11 January 2022
© The Author(s) 2022

Abstract
The widespread adoption of immunotherapy has revolutionized the treatment of various cancer types, including metastatic triple-negative breast cancer (TNBC), which has long been associated with poor prognostic outcomes. In particular, immune checkpoint inhibitors (ICIs) that target and inhibit programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have shown promising results in the treatment of patients with metastatic TNBC. However, while manipulating the immune system to induce antitumor response, ICIs can also lead to a unique set of immune-related adverse events (IRAEs), which differ from standard chemotherapy toxicities due to their immune-based origin. These toxicities require highly specific management, including guidance from multidisciplinary specialists. The primary treatment strategy against IRAEs is systemic corticosteroid use, but additional treatment approaches may also involve supportive care, additional immunosuppression, and concurrent treatment delay or discontinuation. Given the rising prevalence of ICI therapy, it is essential to educate clinicians on the presentation and management of these potentially life-threatening events so that they are identified early and treated appropriately. Using data from recent clinical trials, this review will focus on known IRAEs, particularly those seen in patients with breast cancer, and will summarize their prevalence, severity, and outcomes. We will discuss optimal strategies for early recognition and management, as well as approaches toward cautious retreatment following resolution of IRAEs.

Keywords Breast cancer · Immunotherapy · Immune checkpoint inhibitors · Toxicity · Immune-related adverse events · Retreatment

Introduction
Immune checkpoint inhibitors (ICIs), which block inhibitory pathways that lead to tumor escape and facilitate immune response against tumor cells, have emerged as remarkable treatment options in oncology. ICIs provide antitumor activity by blocking intrinsic downregulators of immunity, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) or its ligand, programmed cell death ligand-1 (PD-L1) [1]. In recent years, the role of ICI therapy has been investigated in patients with breast cancer, which has changed the landscape of breast cancer treatment options for advanced triple-negative disease. Two agents have been approved as first line therapy in combination with chemotherapy for patients with PD-L1+ unresectable locally advanced and metastatic triple-negative breast cancer (TNBC): Atezolizumab, an antibody against PD-L1, and pembrolizumab, an antibody against anti-PD-1 [2–5]. Subsequent clinical trials have shown that the addition of pembrolizumab and atezolizumab to neoadjuvant chemotherapy increases pathologic complete response rates, regardless of PD-L1 status in patients with early-stage TNBC [6, 7]. Immune-related adverse events (IRAEs) most commonly involve the skin, endocrine glands, gastrointestinal system, and liver, but can affect almost any organ system. Other less frequent toxicities impact the cardiovascular, pulmonary, musculoskeletal, ocular, and central nervous systems [1, 8]. Compared to adverse events from chemotherapy, IRAEs typically present with delayed onset and prolonged duration. The majority of immune-related adverse events (IRAEs) are mild to moderate in severity and can be treated with appropriate immunosuppressive agents and/or immunomodulatory strategies in a timely manner; however, serious and rarely
fatal adverse events can also occur. Awareness and management of these toxicities are mandatory in clinical practice. In this review, we briefly discuss the mechanisms of immune-related toxicity, then suggest methods for early diagnosis and effective management of the most common IRAEs from ICI therapy.

**Mechanism of toxicity**

The exact pathophysiology underlying the occurrence of IRAEs is not clear. They are believed to be associated with the role that immune checkpoints play in maintaining immunologic homeostasis. Disinhibition of T-cell function by ICIs may lead to IRAEs. Translational studies have proposed that IRAEs may develop through a combination of pathways involving autoreactive T cells, autoantibodies and cytokines [1]. T-cell activation contributes to the development of IRAEs by leading to the production of inflammatory cytokines and B cell-mediated autoantibodies. There are differences in organ-specific toxicities in patients treated with anti-CTLA-4 therapy or anti-PD-1 therapy. Colitis and hypophysitis occur more frequently with anti-CTLA-4 therapy, whereas pneumonitis and thyroiditis appear to be more common with anti-PD-1 therapy [9–11]. Patients that develop thyroid disorders, while on anti-PD-1 therapy may have antithyroid antibodies, whether they existed at baseline or were detectable only after treatment initiation. One possible explanation of this phenomenon is that anti-PD-1 and anti-PD-L1 treatments, in addition to providing T-cell-mediated immunity, modulate humoral immunity and thereby enhance pre-existing antithyroid antibodies [12]. Studies have demonstrated that IRAEs may also develop through cross-reactive tumoral antigenicity, where the targeted T-cell antigens are present in both tumor and normal tissue [13]. For instance, a prospective study of autoimmune dermatologic toxicity in patients who received anti-PD-1 therapy for non-small cell lung cancer (NSCLC) describes T-cell antigens shared between tumor tissue and skin. Additionally, cytokines may play a role in the mechanism of IRAEs. Elevated levels of IL-17 have been observed in patients with ipilimumab-induced colitis in one clinical study and in preclinical models of colitis [14]. It is not fully understood why IRAEs occur in some patients but not others, but it may be that some patients have a predisposition to autoimmunity. Several studies have investigated the potential risk factors of IRAEs, including history of autoimmune disease, age, ethnicity, increased body mass index, genetic factors, and variations in the microbiologic composition of patients’ gastrointestinal flora [15]. While genetic variations could play a role in the risk of IRAEs, there was no clear evidence to support this [1]. Age does not appear to be a risk factor, as elderly patients tolerate ICIs much like younger patients [16]. Further studies are needed to confirm whether other epidemiologic factors contribute to the likelihood of developing IRAEs [17]. Toxicity differs depending on various therapy combinations. For instance, treatment-related adverse events (TRAEs), which are distinct from IRAEs, are observed more frequently when an ICI is combined with cytotoxic chemotherapy. However, IRAE rates are similar in patients treated with combination therapy as compared to those treated with ICI monotherapy. The only IRAE that appears to increase with combination therapy is pneumonitis, as the incidence of pneumonitis was higher in breast cancer patients treated with ICI and nab-paclitaxel than in those treated with monotherapy [18]. This could be the result of an overlapping toxicity effect, as both immunotherapy and taxanes have the potential to cause pneumonitis. Interestingly, rates of treatment discontinuation with the combination of chemotherapy plus immunotherapy are low compared to CTLA-4 inhibitors alone or immunotherapy combinations [16].

**Immune checkpoint inhibitor-related toxicities**

Onset of IRAEs generally occur within weeks to months of treatment initiation; however, they can develop at any time, even after discontinuation of ICI treatment [8]. IRAEs that arise during treatment with ICIs are termed as acute IRAEs, those that arise after completion of treatment as delayed IRAEs, and those that persist beyond 12 weeks of ICI discontinuation as chronic IRAEs. IRAEs that are likely to become chronic include endocrinopathies, arthritis, xerostomia, neurotoxicity and ocular events, whereas those that affect visceral organs, such as colitis, have much lower rates of becoming chronic [19]. These toxicities can affect almost any organ system and occur with a wide range of presentations, requiring multidisciplinary, collaborative management. As such, early recognition of symptoms and prompt intervention are important for effectively addressing these adverse events. IRAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) from the US National Cancer Institute, which categorizes toxicity on a scale of 1 to 5, in ascending order of severity [20]. In the context of breast cancer in particular, the incidence of IRAEs in those treated with ICI therapy was reported in a meta-analysis including a total of 1746 patients with breast cancer across 27 studies: 34% of patients experienced IRAEs of any grade, and 15% experienced grades 3–4. With anti-PD-1 and anti-PD-L1 treatment specifically, IRAEs were reported in 28% and 53% of patients, respectively. Pembrolizumab (18%) and avelumab (10%) had significantly lower rates of IRAEs as compared to atezolizumab (74%) and nivolumab (81%) [19].
The frequency of IRAEs varies widely according to ICI agent and the organ-specific damage triggered, which may suggest that there is a specific population of individuals who are predisposed to IRAEs. There is no clear evidence explaining why some individuals have a greater tendency toward IRAEs than others, but it has been postulated that there could be a genetic explanation. For instance, some individuals might have a predisposition to autoimmunity [16]. Several studies have suggested an increased risk of IRAEs in patients with pre-existing autoimmune diseases. Previous studies demonstrated that about 10% of patients who developed rheumatic IRAEs had a family history of autoimmune disorders. Genetic variations and the composition of host microbiota could also play a role in the risk of IRAEs [1, 16]. Even so, the role of genetics in determining one’s likelihood of developing IRAEs is not well understood.

**Endocrine toxicity**

Endocrine toxicities associated with ICI therapy include hypothyroidism or hyperthyroidism, thyroiditis, hypophysitis, primary adrenal insufficiency, and insulin-dependent diabetes mellitus. The time to onset of endocrine IRAEs varies by type of agent and endocrinopathy [21]. Unlike other IRAEs, which resolve with treatment, endocrine toxicities are almost always permanent and require lifelong hormone replacement therapy [22].

**Thyroiditis**

The pathogenesis of thyroid disorders following ICIs is not well understood. It is thought to be mediated by T cells rather than B cell autoimmunity [23]. Hypothyroidism is more common than hyperthyroidism in patients treated with ICI therapy. The median reported time to new onset or exacerbation of pre-existing thyroid dysfunction is typically 4–7 weeks after initiation of ICI [24]. Hyperthyroidism is often transient and may precede hypothyroidism [21]. In clinical trials evaluating ICI therapy in patients with breast cancer, the incidence of hypothyroidism of any grade was 4% to 18.0%, whereas the reported rate of hyperthyroidism varied from < 1% to 9.8% (Table 1) [4, 25, 26]. Most thyroid toxicities found in breast cancer patients are reported as grades 1–2, often asymptomatic and detected by routine blood tests (TSH and FT4). Investigation of hypothyroidism should differentiate primary hypothyroidism (in which TSH levels are high and T4 levels are low) from secondary hypothyroidism (characterized by low TSH and T4 levels and hypophysitis or pituitary dysfunction) (Fig. 1). Monitoring, presentation and diagnosis of thyroid disorders following ICIs is provided in Table 2. For patients with primary hypothyroidism, additional testing for thyroid antibodies, including thyroid peroxidase (TPO) antibody, is required. Blood tests such as TSH and free T4 should be carried out at baseline and before every infusion, or at least every 4 to 6 weeks during ICI. This interval can be extended to every 12 to 18 weeks in patients who have normal thyroid function or who experience no symptoms. Patients with asymptomatic and subclinical hypothyroidism who have elevated TSH with normal free T4 can be proceed with ICI, but should be monitored routinely. Levothyroxine can be initiated for TSH levels above 10 mIU/L. Hyperthyroidism can occur during the thyrotoxic phase of thyroiditis, or from other causes of thyrotoxicosis, including Graves disease (defined as high free T4 or total T3 with low or normal TSH). Most commonly, patients with thyroiditis are asymptomatic. Thyroiditis is a self-limiting toxicity that can cause permanent hypothyroidism after the thyrotoxic phase. Thyrotoxicosis is diagnosed with low or suppressed TSH (<0.01 mIU/L), high free T4 and/or total triiodothyronine (T3), and may be symptomatic in the setting of high T4. Presentation of thyrotoxicosis includes weight loss, palpitations, heat intolerance, tremors, anxiety, and diarrhea. If patients are symptomatic, propranolol to manage symptoms until resolution should be considered with endocrine consultation. Testing for TSH receptor antibodies is required when there are clinical features of or suspicion for Graves disease, such as ophthalmopathy. (Table 2) [8, 22].

**Adrenal insufficiency**

Adrenal insufficiency can be seen in cancer patients treated with anti-PD-1 and anti-PD-L1 therapy [27]. Adrenal insufficiency can present as either primary insufficiency or, more commonly, secondary insufficiency referred to as hypophysitis. Symptoms of secondary adrenal insufficiency can be non-specific. Acute symptoms may include headache, photophobia, dizziness, nausea/emesis, fevers, anorexia, visual field cuts or severe fatigue, while chronic symptoms can include fatigue and weight loss. As hypophysitis can affect the thyroid, adrenal or gonadal axes, the following tests should be performed for diagnosis: ACTH, cortisol (AM), follicle-stimulating hormone (FSH), luteinizing hormone (LH), TSH, FT4, electrolytes, testosterone in men, and estrogen in premenopausal women [28]. Low levels of ACTH, AM cortisol, sodium, potassium, testosterone and DHEA-S are indicative of hypophysitis. Brain MR with pituitary/sellar cuts may be performed in patients with multiple endocrine abnormalities with or without new severe headaches or complaint of vision change [22]. Work-up for primary adrenal insufficiency should include serum cortisol, comprehensive metabolic panel and renin levels. If abnormal levels are detected, ACTH, LH, FSH, and testosterone should be evaluated. Primary and secondary adrenal sufficiency can be distinguished by checking the levels of cortisol and ACTH. Hallmarks of primary adrenal insufficiency...
Table 1  Common IRAEs in patients with breast cancer

| Trial                        | Agent     | Ph | #      | Hypothyroidism (%) | Hyperthyroidism (%) | AI (%)<sup>a</sup> | Dermatologic (%) | Hepatitis (%) | Colitis/Diarrhea (%) | Pneumonitis (%) | IRR (%)       |
|-----------------------------|-----------|----|--------|--------------------|---------------------|---------------------|------------------|----------------|-----------------------|----------------|---------------|
|                             |           |    |        | Any Gr ≥ 3         | Any Gr ≥ 3         | Any Gr ≥ 3         | Any Gr ≥ 3       | Any Gr ≥ 3      | Any Gr ≥ 3               | Any Gr ≥ 3      | Any Gr ≥ 3    |
| Trials of immunotherapy in neoadjuvant setting |            |    |        |                    |                     |                     |                  |                |                       |                |               |
| KEYNOTE-522<sup>c</sup> [6] | Pembro + CT | III | 781    | 13.7             | <1                  | 4.6                | <1               | 4.1            | 2.3                  | 3.8            | 1.4           | 1.7          | <1          | 1.3          | <1          | 16.9         | 2.6          |
| I-SPY2 [28]                 | Pembro + CT | II  | 69     | 10.1             | 1.4                 | 5.8                | NR               | 8.7            | 7.2                  | 31.9           | 2.9           | 2.9          | 1.4         | 1.4          | 4.3         | NR          | NR          | NR          |
| IMpassion031 [7]            | Atezo + CT | III | 164    | 7                | NR                  | 3                  | NR               | NR             | NR                   | NR             | 49            | 4            | 1           | 1           | NR          | NR          | NR          | NR          |
| GeparNuevo [42]             | Durva + CT | II-R| 92     | 7.6              | NR                  | 9.8                | NR               | 1.1            | NR                   | 14.1           | 8.7           | 1.1          | NR          | NR          | 1.1         | NR          | 3.3         | NR          |
|                             |           |    |        |                  |                     |                     |                  |                |                       |                |               |              |             |              |             |              |             |             |
| Trials of immunotherapy in advanced and/or metastatic setting |            |    |        |                    |                     |                     |                  |                |                       |                |               |              |             |              |             |             |             |             |
| KEYNOTE-012 [2]             | Pembro    | Ib  | 32     | NR                | NR                  | NR                  | NR               | NR             | NR                   | NR             | NR           | NR           | NR          | NR          | NR          | NR          | NR          | NR          |
| KEYNOTE-086 Coh A [31]      | Pembro    | II  | 170    | 11.8             | NR                  | 5.3                | NR               | NR             | NR                   | NR             | NR           | NR           | NR          | NR          | NR          | NR          | NR          | NR          |
| KEYNOTE-086 Coh B [38]      | Pembro    | II  | 84     | 9.5              | NR                  | 4.8                | NR               | 1.2            | NR                   | NR             | NR           | NR           | NR          | NR          | NR          | NR          | NR          | NR          |
| KEYNOTE-119 [44]            | Pembro + CT | III | 309    | 7.8              | <1                  | 4                  | NR               | 1              | <1                   | 1.6            | 1            | NR           | NR          | NR          | NR          | NR          | NR          | NR          |
| KEYNOTE-355 [5]             | Pembro    | III | 562    | 15               | <1                  | 5                  | NR               | NR             | NR                   | NR             | 2            | 2            | NR          | NR          | 2           | <1          | 2           | 1           | 4           | 1           |
| NCT01375842 [25]            | Atezo     | I   | 116    | 4                | NR                  | NR                 | NR               | 1              | NR                   | 22             | NR           | 8            | NR          | 10          | 1           | 1           | NR          | NR          | NR          |
| IMpassion130 [4, 26]        | Atezo + CT | III | 451    | 18.0             | NR                  | 5                  | <1               | <1             | <1                   | 34             | <1           | 15.3<sup>d</sup> | 5.1       | 1           | <1          | 4.0         | <1          | 1.1         | NR          | NR          | NR          |
| IMpassion131 [37]           | Atezo + CT | III | 431    | 12.8             | NR                  | 5.1                | <1               | NR             | <1                   | 32             | <1           | 1.6          | <1          | <1          | 3.7         | <1          | 3.2         | <1          |             |
| JAVELIN [45]                | Avelumab  | Ib  | 168    | 4.8              | NR                  | <1                 | NR               | <1             | NR                   | 1.8            | 1.8          | NR           | 1.8         | NR          | 1.8         | 14.3        | NR          |             |

# number of patients; AI adrenal insufficiency; Atezo atezolizumab; Coh cohort; Durva durvalumab; Gr grade; IRR infusion-related reactions; NR not reported; Pembro pembrolizumab; Ph phase

<sup>a</sup>Rate of adrenal insufficiency (primary and secondary)

<sup>b</sup>Elevated liver enzymes (AST and ALT)

<sup>c</sup>Adverse events during the neoadjuvant phase at second interim analysis

<sup>d</sup>Hepatitis with diagnoses and lab abnormalities. Diagnoses of any grade: 2.2%, grade 3–4: 1.3%. Lab abnormalities of any grade: 13.7%, grade 3–4: 3.8%
include low morning cortisol (<5) with ACTH above the reference range, and abnormal cosynorphin stimulation test with or without abnormal electrolytes and symptoms. Hypotension, orthostatic hypotension, low sodium and high potassium can also be found. However, patients who develop adrenal insufficiency secondary to ICI-induced hypophysitis have low levels of ACTH and cortisol [22]. It is critical to check morning cortisol in patients who are undergoing surgery on ICI because surgery can bring out symptomatic adrenal insufficiency, which could be life-threatening.

Adrenal insufficiency was observed in 8.7% of breast cancer patients who received pembrolizumab in the I-SPY2 trial. Three of these cases were classified as hypophysitis and one as primary adrenal insufficiency. The remaining two patients were not evaluated due to initiation of steroid therapy prior to work-up [29]. The FDA Oncology Drug Advisory Council met on February 9th, 2021 to review data from KEYNOTE-522. In this interim analysis, 2.2% of patients experienced primary adrenal insufficiency, and 1.9% of patients experienced hypophysitis. One patient died from adrenal crisis on the day following her breast surgery. Her cortisol level was only 3 nmol/L (normal range 172–497), likely representing undiagnosed adrenal insufficiency at the time of surgery [30].

Diabetes mellitus

De novo diabetes mellitus (DM) with ICI therapy occurs at low frequency and can be either type 1 or type 2. Blood glucose levels should be regularly monitored in patients treated with ICIs to detect this. Patients with new-onset polyuria, polydipsia, weight loss, nausea and/or vomiting should be evaluated for possible development of type 1 DM. Fasting glucose is the preferred diagnostic test for suspected new-onset hyperglycemia. The role of steroids to prevent loss of beta cells in the islands of the pancreas is unclear and steroids can negatively affect blood glucose levels. In the KEYNOTE-522 trial, which enrolled patients with early-stage breast cancer to evaluate the addition of pembrolizumab to neoadjuvant chemotherapy, type 1 DM was reported in 2 patients (0.3%). Two patients (1.2%) were diagnosed with type 1 DM with single agent pembrolizumab treatment [31], and 1 patient experience immune-related DM with atezolizumab and nab-paclitaxel combination therapy in the metastatic setting [4].

Non-endocrine toxicities

Dermatologic toxicity

Dermatologic toxicity is common in patients treated with PD-1 or PD-L1 blockade and generally develops early in the course of treatment, within days or weeks, although delayed onset can occur. Severe skin adverse events are rare. Dermatologic toxicities of any grade are reported to occur in <1% to 49% of patients with breast cancer receiving ICI treatment, though the majority of dermatologic toxicity is reported as grades 1 or 2 (Table 1). The presentation of dermatologic IRAEs is diverse. Those most commonly reported are maculopapular rash and pruritus [32]. Although
Table 2 Monitoring, presentation and diagnosis of common IRAEs

| Toxicity          | Monitoring                                                                 | Presentation                  | Diagnosis                                                                                      |
|-------------------|---------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------------------|
| Endocrine         |                                                                           |                               |                                                                                               |
| Thyroid           | TSH & free T4 at baseline and every 4–6 weeks during ICI, with follow up every 12 weeks thereafter, as indicated | Hypothyroidism                | TSH, free T4                                                                                   |
|                   |                                                                           | Hyperthyroidism               | Morning cortisol level for concurrent adrenal insufficiency                                    |
|                   |                                                                           | Myxedema                      | TSH receptor antibodies if Graves disease is suspected                                          |
|                   |                                                                           | Thyroid storm                 | Lab: Evaluate morning cortisol and ACTH                                                        |
| Adrenal insufficiency | TSH & free T4 at baseline and every 4–6 week on ICI                     | Hypophysitis                  | TSH, free T4                                                                                   |
|                   | Consider baseline ACTH and cortisol in high risk patients               | Dysfunction of thyroid, adrenal or gonadal axis  | LH, FSH, testosterone (men), estradiol (women)                                                 |
|                   |                                                                           | Symptoms: Headache, dizziness, nausea/ emesis, anorexia, fatigue | Imaging: MRI of sella                                                                         |
|                   |                                                                           |                               | Secondary adrenal insufficiency: Low ACTH, low cortisol                                        |
|                   |                                                                           |                               | Central hypothyroidism: Low TSH, low free T4                                                  |
| Non-endocrine     |                                                                           |                               |                                                                                               |
| Dermatologic      | Complete skin and mucous membrane examination                           | Rash, pruritus, bullous dermatitis             | Rule out alternative etiology of skin problem (e.g., infection, other drug rash, skin lesion linked to another systemic disorder) |
|                   | Review prior immune-related skin disorders                               | Dermatomyositis                | Complete skin examination and determination of lesion type                                     |
|                   |                                                                           | Dermal hypersensitivity reaction | Consider skin biopsy                                                                          |
|                   |                                                                           | Sweet syndrome                |                                                                                               |
|                   |                                                                           | Pyoderma gangrenosum          |                                                                                               |
| Hepatitis         | Comprehensive metabolic panel (serum transaminase and bilirubin) at baseline | Elevation of AST/ALT           | Comprehensive metabolic panel                                                                 |
|                   | Repeat every 2–3 weeks during ICI                                        | Fulminant hepatitis           | Rule out infectious causes: viral studies                                                      |
|                   |                                                                           |                               | Rule out drug-induced hepatitis, including alcohol                                             |
|                   |                                                                           |                               | Rule out autoimmune hepatitis suspected                                                        |
|                   |                                                                           |                               | Rule out NASH and thrombosis                                                                  |
|                   |                                                                           |                               | Abdomen CT to evaluate liver metastases                                                       |
| Diarrhea or colitis | Evaluate baseline bowel habits                                          | Diarrhea                      | Consider liver biopsy                                                                         |
|                   | Follow up any GI symptoms and signs                                       | Urgency                       | Evaluate baseline bowel habits                                                                |
|                   |                                                                           | Abdominal pain and/or cramping | CBC, Comprehensive metabolic panel, ESR, TSH, CRP                                              |
|                   |                                                                           | Fever                         | Rule out infection: stool culture, Clostridium difficile, CMV DNA PCR, stool ova and parasites |
|                   |                                                                           |                               | Consider lactoferrin/calprotectin                                                              |
|                   |                                                                           |                               | CT Abdomen/pelvis                                                                             |
|                   |                                                                           |                               | Consider GI consultation for EGD/colonoscopy with biopsy                                      |
Breast Cancer Research and Treatment (2022) 192:1–17

less frequent, psoriasis and lichenoid, eczematous, and bullous dermatitis have also been reported in patients treated with ICI [33]. The first step when ICI-treated patients present with skin AEs should be to rule out any other etiologic factors that could be contributing to the skin condition, such as an infection, a drug-induced lesion, or a skin condition linked to another systemic disorder. Next, the grade of dermatologic toxicity and the general patient status must be evaluated. Blood tests, including blood cell count, liver tests and kidney tests, will help evaluate for dermatological emergencies, such as drug rash with eosinophilia and systemic symptoms (DRESS), acute febrile neutrophilic dermatosis (Sweet syndrome), Stevens-Johnson syndrome, or toxic epidermal necrolysis (TEN) [8, 22, 34].

Immune-related hepatitis

Hepatitis occurs in 1%-6.3% of patients with breast cancer receiving ICI therapy (Table 1). Immune-related hepatitis is typically mild, but can be severe or even fatal in rare cases. The most common presentation of immune-related hepatitis is asymptomatic with aspartate transaminase (AST) and alanine transaminase (ALT) abnormalities, with or without hyperbilirubinemia. Median onset of transaminase elevation is approximately 3–9 weeks after starting ICI therapy [24]. Serum transaminases and bilirubin should be measured prior to initiation of ICIs and before every cycle of ICI treatment. The differential diagnosis of transaminase elevation during ICI treatment includes disease-related causes, concomitant drug intake including alcohol, and infectious causes, especially viral hepatitis. However, initiation of therapy for IRAEs should not be delayed while pending serological results if there is no other obvious cause. Liver biopsy can be considered to assess more severe hepatic reactions, such as transaminase levels greater than five times the upper limit of normal (Table 2) [8, 22].

Gastrointestinal toxicity

Gastrointestinal (GI) toxicity may present with symptoms of colitis, including watery diarrhea, cramping, and urgency. Diarrhea has an incidence of ~20% in patients treated with anti-PD-1 therapy; however, colitis with evidence of colon inflammation is only reported in 1% of such patients. Colitis is more commonly seen with anti-CTLA-4 monotherapy than with anti-PD-1/PD-L1 inhibitors [35]. Anti-CTLA-4 drugs, such as ipilimumab and tremelimumab, have not been approved in the treatment of patients with breast cancer, but there are many ongoing trials investigating the therapeutic role of ipilimumab in breast cancer. In addition to diarrhea, the presence of abdominal pain, rectal bleeding, mucus in the stool, and fever should raise suspicion for colitis, which is a potentially life-threatening complication of ICI.
treatment. The investigation of potential infectious causes should be performed in diagnosing ICI-related colitis. CT exams should also be performed to evaluate the extent and severity of colitis and to rule out bowel perforation. Endoscopy, while not routine for mild cases, can help diagnose patients with refractory or recurrent colitis and distinguish from cytomegalovirus associated colitis [32]. Colon biopsy findings of colitis typically reveal a mixed lymphocytic and neutrophilic infiltrate with apoptotic mucosal epithelial cells and crypt abscesses [36]. Associated diffuse enteritis can be seen simultaneously in patients with or without colitis. Upper GI symptoms, such as dysphagia and epigastric pain, have been reported. Endoscopic lesions outside the colon, including esophageal ulcerations, gastritis and duodenitis, can also occur. Stool culture for bacterial enteropathogens and stool analyses for Clostridium difficile toxin should be obtained to rule out infectious etiology. Diarrhea and colitis have been reported in <1% to 12.5% of patients with breast cancer treated with ICI (Table 1). The majority of these cases are low grade and manageable with appropriate care [2, 37, 38]. Diarrhea and/or colitis may recur months after discontinuation of ICI therapy, and cases like these must be distinguished from inflammatory bowel disease [39].

Pneumonitis

Pneumonitis is the most common pulmonary toxicity of ICI therapy and has variable onset, clinical presentation, and imaging findings [8]. The overall incidence of pneumonitis is low with reported rates of 1–4.1% in patients with breast cancer (Table 1) [25, 31]. However, it is potentially life-threatening and should be assessed by CT in any patient who develops new respiratory symptoms, such as new cough, shortness of breath or hypoxia, chest pain, fatigue with activities of daily living (ADL), and new or increasing requirement for supplementary oxygen during ICI treatment. In one case, a breast cancer patient with malignant pleural effusion presented with dry cough, dyspnea, and fever after receiving pembrolizumab treatment. A chest CT showed ground glass opacity, and a transbronchial lung biopsy revealed focal septal lymphocytic infiltration. The patient recovered with 1.0 mg/kg/day steroid therapy [40].

In general, as pulmonary symptoms and signs can sometimes suggest disease progression, particularly in the context of lung metastases, any new respiratory symptom should be evaluated carefully. Some asymptomatic patients are diagnosed incidentally on imaging studies [10]. Imaging findings are variable and can include cryptogenic organizing pneumonia, non-specific interstitial pneumonitis, hypersensitivity pneumonitis, or usual interstitial pneumonitis/pulmonary fibrosis [8]. Pre-existing pulmonary fibrosis or chronic obstructive pulmonary disease can delay the diagnosis of immune-related pneumonitis. Acute interstitial pneumonitis/diffuse alveolar damage syndrome is the most acute life-threatening event. Even though pneumonitis can be observed at any time, patients commonly experience pneumonitis months after treatment initiation, which is later than other IRAEs. In general, lung biopsy is not required for management of patients, but can be considered if there is any suspicion of acute infection or lymphangitic spread of lung metastases. Alternatively, bronchoscopy with bronchoalveolar lavage is sometimes recommended by a pulmonologist for symptomatic pneumonia and can be helpful to identify infections, including potential opportunistic or atypical agents (Table 2).

Rare immune-related adverse events

Neurologic toxicity

Neurologic IRAEs occur rarely in patients receiving ICI, but can cause substantial morbidity if not recognized and treated early. Neurologic IRAEs are reported to occur within 4.5 weeks of initiation of anti-PD-1 therapy [41]. A range of neurological events have been described in patients with breast cancer, including headache, encephalitis, aseptic meningitis, peripheral neuropathy, adverse events affecting cranial nerves, myasthenia gravis, and Guillain-Barre like syndrome (GBS)[2, 4, 6, 7, 25, 42]. Additionally, central neuropathy and transverse myelitis were reported with previous ICI trials in patients with variable solid tumors. The most commonly reported neurologic toxicities were headache, encephalopathy, meningitis and Myasthenic syndrome, and a majority of these events were low grade [41]. Previous trials have reported severe neurologic IRAEs resulting in fatality, such as encephalitis and myasthenia gravis. The presentation of neurologic IRAEs can be diverse with non-specific symptoms. Peripheral neuropathies have been reported with ICIs in which nerve conduction studies are helpful. Patients with myasthenia gravis are presented with progressive or fluctuating muscle weakness, generally proximal to distal. Bulbar involvement and/or respiratory muscle weakness are features of ICI-related myasthenia gravis. Patients presenting with headaches, neck stiffness and photophobia during ICI therapy should be investigated for aseptic meningitis. In addition to these symptoms described, patients who present with altered mental status and/or seizures should be evaluated for potential encephalitis. It is necessary to rule out other potential factors, such as progression of breast cancer, central nervous system (CNS) metastasis or leptomeningeal spread, paraneoplastic syndrome, vitamin B12 deficiency, diabetic neuropathy, seizure activity, infection and metabolic derangement. Recommended assessments include brain MR, spine MR, lumbar puncture, and electroencephalography (EEG). Appropriate laboratory tests should be performed depending on the potential causes of neurologic toxicity.
Neurology consultation should be considered if there is suspicion for severe neurologic toxicities such as myasthenia gravis, Guillain–Barre syndrome (GBS), aseptic meningitis, encephalitis or transverse myelitis [8, 22, 43].

**Cardiovascular toxicity**

IRAEs of the cardiovascular system are rare, but potentially permanent and/or fatal. A range of cardiac events have been reported after treatment with ICIs, including myocarditis, pericarditis, arrhythmias, cardiomyopathy and impaired ventricular function, acute heart failure and cardiac arrhythmia. Myocarditis is one of the most common cardiovascular toxicities and occurs within 4 weeks of ICI therapy initiation. In some patients with cardiac IRAEs, severe adverse events, such as myositis and myocardia gravis, were reported concurrently with myocarditis. Clinical presentation of cardiac IRAEs can include fatigue, weakness, dyspnea, chest pain, palpitations or symptoms of congestive heart failure, depending on the type of cardiac dysfunction [8]. Electrocardiography and cardiac serum biomarkers including creatinine kinase and troponin levels should be checked to investigate cardiac toxicity. Additionally, echocardiography to assess left ventricular fraction and cardiac MR with gadolinium enhancement to assess inflammation secondary to myocarditis are useful diagnostic tools [22]. Endomyocardial biopsy is the gold standard for the diagnosis; however, it is rarely performed as the first step in diagnosis due to its invasiveness [44]. Additionally, it has low sensitivity and high interobserver variability in interpretation of biopsy samples [45]. For these reasons, endomyocardial biopsies are only recommended for uncommon presentations of myocarditis [46].

**Rheumatologic toxicity**

Identifying rheumatologic IRAEs in patients with cancer is challenging due to the difficulty in distinguishing these IRAEs from other musculoskeletal complaints, as this patient population has a high baseline frequency of musculoskeletal symptoms. Myalgias, arthralgias, inflammatory arthritis and polymyalgia rheumatica are the most common IRAEs. Joint examination, functional assessment of joints, imaging modalities, and occasionally laboratory tests can be helpful for diagnosis. Variable presentations of rheumatologic IRAEs have been reported, including sicca syndrome, myositis, giant cell arthritis, systemic lupus erythematosus, and sarcoidosis. Rarely, severe myositis presenting with muscle weakness and elevated creatine kinase (CK) can be fatal and has been reported more commonly in patients receiving PD-1/ PD-L1 inhibitors. Rheumatologic IRAEs such as arthralgia, myalgia, pain in extremities, back pain, dry eye, xerostomia, elevated rheumatoid factor, anti-nuclear antibody (ANA) positivity and myositis have been reported in patients with breast cancer receiving ICI treatment [2, 6, 47, 48]. Early rheumatology consultation and the introduction of disease-modifying drugs beyond steroids can help optimize treatment and prevent irreversible joint damage [8, 49].

**Renal toxicity**

Renal IRAEs are rare in patients with breast cancer treated with ICI therapy. Recent studies suggested that the incidence of IRAEs may be under-reported due to mild symptoms and signs [50]. Presentation varies and can include elevated serum creatinine, electrolyte imbalance, altered urinary output and worsening hypertension. Nephritis, hypotension, hypertension and hypokalemia have been reported in previous clinical trials involving breast cancer patients treated with ICIs. The differential diagnosis for patients who develop renal dysfunction on ICIs includes infection, dehydration, nephrotoxic drugs, urinary tract obstruction, contrast agents. Serum sodium, potassium, creatinine and urea should be measured before every infusion of ICI therapy. In addition, urinary protein followed by autoimmune markers, such as anti-nuclear antibody, anti-neutrophil cytoplasmic antibody, rheumatoid factor, anti-double-stranded DNA antibodies and serum complement levels, might be helpful toward understanding the underlying pathological process [22]. Clinical findings and laboratory tests are not ideal in diagnosing underlying renal lesions, so kidney biopsies are necessary to definitively diagnose the type of renal damage. Acute interstitial nephritis, minimal change disease, lupus-like disease and acute thrombotic microangiopathy have been reported as pathologic findings with ICI treatment [50, 51].

**Ocular toxicity**

Variable ocular IRAEs occur depending on the affected area of the eye. These can include retinal choroidal disease, optic neuropathy, or various presentations of ocular inflammation, such as peripheral ulcerative keratitis, uveitis, episcleritis, blepharitis, orbital inflammation and orbitopathy (idiopathic or thyroid-induced orbitopathy) [52]. The most commonly reported IRAEs are dry eye and uveitis. Patients can present with blurred or distorted vision, changes in color vision, blind spots, photophobia, eye pain, eyelid swelling, and proptosis. Episcleritis can be associated with red or purple discoloration of the eye, and uveitis may present with eye redness. Ocular toxicity has been reported concurrently with extraocular IRAEs, particularly colitis [52, 53]. While oncologists can perform penlight inspection or examine patients for visual acuity and color vision, referral to ophthalmology is recommended for all those patients who experience visual symptoms with
ICI therapy. In patients with breast cancer, dry eye, uveitis, and ocular inflammatory toxicities were reported during ICI therapy in clinical trials. In one case of a patient with mTNBC, acute macular neuroretinopathy was reported after receiving atezolizumab [54].

Hematological toxicities

Hematological IRAEs have been reported in patients treated with ICI, although rarely. Examples include neutropenia, thrombocytopenia, myelodysplasia, aplastic anemia, autoimmune hemolytic anemia and immune thrombocytopenic purpura. Cytopenia that is persistent or progressive after receiving ICI therapy should be investigated for autoimmune causes. The differential diagnosis for cytopenia includes cancer progression, bone marrow involvement, gastrointestinal bleeding and drug effect [55]. As the optimal management of hematological toxicities is largely unknown, prompt consultation with a hematologist is recommended to initiate high dose corticosteroid and/or other immunosuppressive drugs [8].

Infusion-related reactions

During or following infusion with ICIs, patients can present with constitutional symptoms such as fever, rigor, pruritus, hypotension, dyspnea, chest comfort, rash, urticaria, angioedema, wheezing or tachycardia, and rarely anaphylaxis requiring urgent intervention. In the literature, infusion reactions have been reported most commonly with avelumab. In the JAVELIN trial, for instance, 14.3% of patients with breast cancer experienced infusion reactions of any grade after treatment with avelumab [48]. The rates of all grades infusion-related reactions range from 1.1 to 16.9% in patients with breast cancer receiving ICI (Table 1) [4, 6]. Most infusion reactions are mild and present with low-grade fever, chills, headache or nausea; however, severe reactions of grades 3–4 have been reported in <1% to 2.6% of patients with breast cancer in clinical trials (Table 1). Mild to moderate reactions are managed with a variety of methods, including symptomatic treatment, reducing the rate of infusions, temporarily interrupting infusions, or adding premedication for subsequent infusions, while severe reactions should be managed urgently with anti-histamines, oxygen, fluids, opioids, corticosteroids and bronchodilators. Permanent discontinuation of the ICI is recommended when grade 3–4 infusion reactions occur [8, 22].

Management of immunotherapy-related toxicities

ICB-related toxicities result from excessive host immune response directed against normal organs. As such, most IRAEs can be treated by inducing temporary immunosuppression with oral corticoids, high dose steroid therapy (oral prednisolone 1–2 mg/kg/day or IV equivalent), or additional immunosuppressants in more severe cases. Proton pump inhibitor or H2 blockers for gastrointestinal prophylaxis can be considered with high dose steroid treatment. For steroid-refractory cases, including patients with severe IRAEs that are not responsive to steroids within 48–72 h, early initiation of additional immunosuppressants or plasmapheresis can be considered with close guidance from a disease-specific subspecialist. Examples of these immunomodulatory agents include infliximab, tumor necrosis factor inhibitors (TNFi), mycophenolate mofetil, antithymocyte globulin (ATG), calcineurin inhibitors, methotrexate, or intravenous gammaglobulin (IVIG). Guidance on prescribing routine prophylactic antibiotics to reduce the potential opportunistic infection in patients receiving steroids remains unclear. For patients receiving at least 20 mg prednisone or equivalent/day for ≥4 weeks, the addition of prophylactic antibiotics for pneumocystis pneumonia (PCP) can be considered [8, 22]. Prophylaxis against fungal infections (e.g., fluconazole) is recommended in patients receiving prednisone ≥20 mg daily for ≥6–8 weeks. The management of immunotherapy toxicities should depend on grade of severity, type, and number of adverse events. Patient’s medical history, comorbidities, underlying disease status, and ability to tolerate corticosteroids must be incorporated into decisions about optimal treatment strategies. The management of IRAEs is summarized in Table 3.

In general, ICI treatment can be continued with close monitoring for grade 1 IRAEs, with the exception of some neurologic, hematologic and cardiac toxicities. For patients who experience grade 2 IRAEs, steroid treatment with 0.5–1 mg/kg prednisone/equivalent is recommended and ICI therapy should be held until toxicity resolves to Grade ≤1. For Grade 3 IRAEs, ICI treatment should be held, and dose adjustment is not recommended. Cautious retreatment with ICIs can be considered when IRAEs revert to Grade ≤1. Patients should be treated with high dose steroids (oral prednisolone 1–2 mg/kg/day or IV equivalent) until resolution to ≤ Grade 1, at which point steroid treatment should taper slowly over 4–6 weeks. In some cases, longer steroid tapers (6–8 weeks or more) may be required to prevent recurrent IRAEs, especially with pneumonitis and hepatitis. If there is no improvement with steroids in 1–3 days, other immunosuppressant and immunomodulatory agents can be considered. Among 5363 patients that received ICI therapy between 2013 and 2020, 6.8% required additional immunosuppressant agents for IRAEs [56]. All patients who experience grade 4 IRAEs should permanently discontinue ICI therapy, with the exception of patients with grade 4 endocrinopathies controlled by hormone replacement. Patient with hypothyroidism and asymptomatic thyroiditis can continue ICI treatment. For patients with
| Toxicity                        | CTCAE-V5 classification [19]                                                                 | Management [17, 21]                                                                 |
|-------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Common endocrine IRAEs**    |                                                                                               |                                                                                 |
| **Thyroid**                    | Grade 1: Asymptomatic; clinical or diagnostic observations only                                | Symptomatic hypothyroidism: Thyroid hormone replacement if TSH > 10 mIU/L         |
|                               | Grade 2: Moderate symptoms; medical intervention indicated                                      | Hyperthyroidism: If symptomatic, consider endocrine consultation and propranolol for symptom control |
|                               | Grade 3: Severe symptoms; limiting self-care ADL; medical intervention or hospitalization required | ICI can be continued in the setting of hypothyroidism or thyrotoxicosis           |
|                               | Grade 4: Life-threatening consequences; urgent intervention indicated                           |                                                                                 |
|                               | Asymptomatic hypothyroidism: Thyroid hormone replacement if TSH > 10 mIU/L                    |                                                                                 |
|                               | Symptomatic hypothyroidism: Thyroid hormone replacement                                       |                                                                                 |
| Adrenal Insufficiency          | Grade 1: Asymptomatic or mild; clinical or diagnostic observations only                        | Endocrine consultation                                                           |
|                               | Grade 2: Moderate symptoms; minimal; local or non-invasive intervention indicated              | Hold ICI until acute symptoms resolve, and hormone replacements are initiated     |
|                               | Grade 3: Severe or medically significant but not immediately life-threatening;                 | Treat with hormone replacement as indicated                                       |
|                               | hospitalization indicated                                                                     | • Secondary adrenal insufficiency: steroid replacement (physiologic steroid replacement hydrocortisone 20 mg AM, 10 mg PM). Acutely symptomatic or hospitalized patients may require stress dose hydrocortisone (e.g., 50 mg every 6–8 h) |
|                               | Grade 4: Life-threatening consequences; urgent intervention indicated                           | • Central hypothyroidism: Thyroid hormone replacement and follow free T4 level for dose titration |
|                               | Endocrine consultation                                                                        |                                                                                 |
|                               | Hold ICI until acute symptoms resolve, and hormone replacements are initiated.                 |                                                                                 |
|                               | Treat with hormone replacement as indicated                                                   |                                                                                 |
|                               | • Secondary adrenal insufficiency: steroid replacement (physiologic steroid replacement hydrocortisone 20 mg AM, 10 mg PM). Acutely symptomatic or hospitalized patients may require stress dose hydrocortisone (e.g., 50 mg every 6–8 h) |                                                                                 |
|                               | • Central hypothyroidism: Thyroid hormone replacement and follow free T4 level for dose titration |                                                                                 |
| **Common non-endocrine IRAEs** |                                                                                               |                                                                                 |
| **Dermatologic**               | Grade 1: Macules/papules covering <10% the BSA with or without symptoms (pruritus, burning, tightness) | Grade 1: Emollients, topical corticosteroids and/or oral or topical anti-histamines. Avoid skin irritants, avoid sun exposure. Proceed with ICI treatment |
|                               | Grade 2: Macules/papules covering 10–30% BSA with or without symptoms (pruritus, burning, tightness); limiting instrumental ADL | Grade 2: High potency topical corticosteroids, and/or oral steroids. Proceed with ICI |
|                               | Grade 3: Macules/papules covering >30% BSA with or without associated symptoms: Limiting self-care ADL | Grade 3–4: Withhold ICI. Treat with systemic 1–2 mg/kg/d steroids and dermatology consultation. Treat until symptoms improve to grade ≤ 1 then taper over 4–6 weeks |
|                               | Grade 4: Papulopustular rash associated with life-threatening superinfection;                 | • Consider IVIG or rituximab for grade ≥ 3 bullous dermatitis                    |
|                               | SJ/TEN, bullous dermatitis covering >30% of BSA and requiring ICU admission                   | • Permanently discontinue ICI treatment if grade 4 or SJ/TEN                      |
|                               |                                                                                               | • Consider gabapentin/pregabalin for grade ≥ 3 pruritus                          |
| **Hepatitis**                  | Grade 1: ALT or AST > ULN-3×ULN                                                               | Grade 1: Continue ICI treatment with increased frequency of LFT monitoring       |
|                               | Grade 2: ALT or AST 3–5×ULN                                                                  | Grade 2: Hold ICI until recovery to grade ≤ 1; start systemic 0.5-1 mg/kg/d if no improvement |
|                               | Grade 3: 5–20×ULN                                                                            | Grade 3–4: Hold ICI; monitor liver enzymes, hepatology consult; start 1–2 mg/kg/d steroids |
|                               | Grade 4: >20×ULN                                                                             | Grade 4: Permanently discontinue ICI; start 1–2 mg/kg/d steroids                |
|                               |                                                                                               | Grade > 1 transaminitis with elevated bilirubin:                                 |
|                               |                                                                                               | • Bilirubin 1–2×ULN: hold ICI, initiate 1–2 mg/kg/d steroids                     |
|                               |                                                                                               | • Bilirubin 3–4×ULN: permanently discontinue ICI; initiate 1–2 mg/kg/d steroids  |
|                               |                                                                                               | For steroid-refractory cases, or if no improvement after 3 days, consider       |
|                               |                                                                                               | mycophenolate mofetil and cyclosporine; infliximab is contraindicated because of concerns about hepatotoxicity |
### Table 3 (continued)

| Toxicity          | CTCAE-V5 classification [19]                                                                                                                                                                                                 | Management [17, 21]                                                                                                                                                                                                 |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Diarrhea**      | Grade 1: Increase of < 4 stools per day over baseline  
Grade 2: Increase of 4–6 stools per day over baseline; limiting instrumental ADL  
Grade 3: Increase of ≥ 7 stools per day over baseline; hospitalization indicated; limiting self-care ADL  
Grade 4: Life-threatening consequences; urgent intervention indicated | Grade 1: Symptomatic management: oral fluids, loperamide, avoid high fiber/lactose diet  
Grade ≥ 2: Hold ICI until recovery to grade ≤ 1; evaluate for infection; start 1–2 mg/kg/d steroids; gastroenterology consult. If no response within 3–5 d, consider adding infliximab. In refractory cases or cases with a contraindication to infliximab, vedolizumab can be used; earlier initiation of biologic therapy may lead to improved outcomes  
Grade 3: Discontinue ICI; consider resuming anti-PD-1 or anti-PD-L1 after resolution of toxicity  
Grade 4: Permanently discontinue ICI                                                                 |
| **Pneumonitis**   | Grade 1: Asymptomatic; radiographic changes only ground glass change, non-specific interstitial pneumonia  
Grade 2: Symptomatic; medical intervention indicated; limiting instrumental ADL  
Grade 3: Severe symptoms; limiting self-care ADL; oxygen indicated  
Grade 4: Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation) | Grade 1: Consider holding ICI, reassess in 1–2 weeks, consider CT Chest  
Grade 2: Hold ICI; consider pulmonary consultation; consider empiric antibiotics; initiate 1–2 mg/kg/d steroids. If no improvement after 48–72 h of steroids, treat as grade 3  
Grade 3–4: Permanently discontinue ICI; pulmonary and infectious disease consultation; consider empiric antibiotics; initiate 1–2 mg/kg/d steroids; assess steroid response within 48 h and plan taper over 6 weeks or longer. If no improvement after 48 h, consider adding infliximab, IVIG or mycophenolate mofetil |
| **Rare IRAEs**     |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                   |
| **Neurologic**    | Grade 1: Mild symptoms  
Grade 2: Moderate symptoms; limiting instrumental ADL  
Grade 3: Severe symptoms, limiting self-care ADL  
Grade 4: Life-threatening consequences; urgent intervention indicated | Grade 1: Consider holding ICI  
Grade 2: Hold ICI, permanently discontinue if moderate encephalitis  
Grade 3–4: Permanently discontinue ICI  
Permanently discontinue ICI if: Guillain-Barre Syndrome, Transverse Myelitis, or Myasthenia Gravis  
Consider steroids according to guidelines, IVIG, plasmapheresis, or IV acyclovir  
Gabapentin, pregabalin or duloxetine for pain |                                                                                                                                                                                                                   |
| **Cardiovascular**| Grade 1: Asymptomatic; abnormal cardiac biomarker testing, including abnormal ECG  
Grade 2: Abnormal screening tests with mild symptoms  
Grade 3: Moderately abnormal testing or symptoms with mild activity, intervention indicated  
Grade 4: Moderate to severe decompensation, intravenous medication or intervention required, life-threatening conditions | Grade 1: Mild abnormalities should be observed closely during therapy  
Grade 2: Control cardiac disease and cardiac disease risk factors  
Grade 3: Consider withholding ICI  
Grade 4: Permanently discontinue ICI  
Myocarditis/Pericarditis: Permanently discontinue ICI  
Initiate 1 mg/kg/d steroids. If no improvement within 24 h, consider adding other immunosuppressive and/or immunomodulatory agents |                                                                                                                                                                                                                   |
| **Rheumatologic** | Grade 1: Mild pain with inflammatory symptoms, erythema, or joint swelling  
Grade 2: Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL  
Grade 3: Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; disabling; limiting self-care ADL | Mild: Supportive care, continue ICI. Consider holding ICI if mild myositis  
Moderate/severe: Hold ICI, administer corticosteroids  
For steroid-refractory cases, consider adding other immunosuppressive and/or immunomodulatory agents |                                                                                                                                                                                                                   |
| Toxicity       | CTCAE-V5 classification [19]                                                                 | Management [17, 21]                                                                 |
|---------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Renal         | Grade 1: cre 1.5–2× above baseline<br>Grade 2: cre 2–3× above baseline<br>Grade 3: cre > 3× above baseline or 4.0 mg/dL<br>Grade 4: Life-threatening consequences; dialysis indicated | Grade 1: Supportive care, consider holding ICI<br>Grade 2: Hold ICI, consider renal biopsy if feasible prior to starting steroids, nephrology consultation, initiate 0.5–1 mg/kg/d steroids for persistent grade 1–2 beyond 1 week, increase steroid to 1–2 mg/kg/d. Upon improvement to grade 1, start to taper corticosteroids<br>Grade 3–4: Hold ICI, consider renal biopsy if feasible prior to starting steroids, nephrology consultation, start 1–2 mg/kg/d steroids<br>For steroid-refractory cases, consider adding other immunosuppressive and/or immunomodulatory agents |
| Ocular        | Grade 1: Asymptomatic; clinical or diagnostic observations only<br>Grade 2: Symptomatic, limiting instrumental ADL; moderate decrease in visual acuity; anterior uveitis<br>Grade 3: Symptomatic, limiting self-care ADL; marked decrease in visual acuity; posterior or pan-uveitis<br>Grade 4: Blindness | Ophthalmology evaluation and vision tests (visual acuity, color vision, red reflex, fundoscopic examination, pupil size, shape, and reactivity)<br>Grade 1: Continue ICI or hold to observe for worsening uveitis<br>Grade 2: Hold ICI, coordinate treatment with ophthalmologist<br>Grade 3–4: Permanently discontinue ICI, administer ophthalmic or systemic corticosteroids<br>For steroid-refractory cases, consider adding infliximab or methotrexate for pan-uveitis |

ADL activities of daily living; ALT alanine transaminase; AST aspartate transaminase; BSA body surface area; cre, creatinine; CT computed tomography; CTCAE Common TerminologyCriteria for Adverse Events; d day; ICI immune checkpoint inhibitor; IVIG intravenous immunoglobulin; LFT liver function test; SJS/TEN Stevens-Johnson syndrome or toxic epidermal necrolysis; TSH thyroid-stimulating hormone; ULN upper limit of normal
adrenal insufficiency who are hemodynamically unstable, it is recommended to hold ICI therapy until acute symptoms resolve and hormone replacement therapy is initiated [22]. Treatment for most IRAEs is typically limited to a few months, but management of thyroid disorders and adrenal insufficiency with hormone replacement therapy is generally expected to be lifelong even though it is unknown whether lifelong hormone replacement therapy is necessary. Although thyroid and adrenal disorders are managed with hormone replacement therapy and not steroid therapy, we do not know whether steroids could be useful in reversing the inflammatory process.

Immune checkpoint inhibitor-related fatal AEs

In rare cases, serious adverse events observed with ICI therapy have been fatal. Life-threatening IRAEs reported in previous clinical trials include severe colitis, pneumonitis, encephalitis, toxic epidermal necrolysis, myocarditis, adrenal insufficiency and autoimmune type 1 DM presenting as diabetic ketosis in patients with breast cancer. ICI-related deaths may be increased with delayed diagnosis and treatment. Additionally, complications secondary to the primary adverse event can cause other severe symptoms potentially leading to death, such as infection with immune-related colitis. In a meta-analysis of patients treated with ICIs, the incidence of death from IRAEs differed based on the immunotherapy agent used; fatality rates were 0.36% with anti-PD-1, 0.38% with anti-PD-L1, 1.08% with anti–CTLA-4, and 1.23% with combined anti–PD-1/anti–PD-L1 and CTLA-4 therapy. Another meta-analysis, which included 46 studies and a total of 12,808 patients treated with anti-PD-1/anti–PD-L1, reported a fatality rate of 0.17% [50]. Incidence of death due to IRAEs also varied across tumor types. In a meta-analysis investigating 3713 patients treated with pembrolizumab, fatality rates from IRAEs in breast cancer and melanoma were 3.1% and 0.2%, respectively [51]. Fatal IRAEs varied for different treatment regimens. The most common fatal IRAE with anti–CTLA-4 therapy was colitis (70%), whereas pneumonitis (35%), hepatitis (22%), and neurotoxicity (15%) were most often seen with anti–PD-1/anti–PD-L1 therapy [57]. Fatal IRAEs reported in patients with breast cancer are summarized in Table 4.

Safety of retreatment with immunotherapy after immune-related toxicity

One of the most important issues in clinical practice is the safety of retreatment with immunotherapy following immune-related toxicity. In prospective clinical trials, ICI therapy must be permanently discontinued if a serious IRAE

### Table 4 Fatal IRAEs reported in clinical trials in patients with breast cancer

| Trial | Agent | Number | Fatal adverse events |
|-------|-------|--------|----------------------|
| Trials of immunotherapy in neoadjuvant setting | | |
| KEYNOTE-522 [6, 30] | Pembro + CT | 5 | TRAEs: Sepsis, MODS, MI (n = 1), pneumonitis (n = 2) |
| | | | 2 patients died due to IRAEs: Adrenal crisis (n = 1), autoimmune encephalitis (n = 1) |
| I-SPY2 [29] | Pembro + CT | NR | – |
| IMpassion031 [7] | Atezo + CT | NR | – |
| GeparNuevo [42] | Durva + CT | NR | – |
| Trials of immunotherapy in advanced and/or metastatic setting | | |
| KEYNOTE-012 [2] | Pembro | 1 | Grade 4 decreased blood fibrinogen, DIC |
| KEYNOTE-086 Coh A [31] | Pembro | NR | – |
| KEYNOTE-086 Coh B [38] | Pembro | NR | – |
| KEYNOTE-119 [44] | Pembro | 1 | Circulatory collapse |
| KEYNOTE-355 [5] | Pembro + CT | 2 | TRAEs: Acute kidney injury (n = 1), pneumonia (n = 1) |
| | | | No patients died due to IRAEs |
| NCT01375842 [25] | Atezo | 2 | Pulmonary HT (n = 1), not otherwise specified in a hospitalized patient (n = 1) |
| IMpassion130 [4, 26] | Atezo + CT | 3 | TRAEs: Autoimmune hepatitis (n = 1), mucosal inflammation (n = 1), septic shock (n = 1) |
| | | | No patients died due to IRAEs |
| IMpassion131 [37] | Atezo + CT | 1 | Polymyositis (n = 1) |
| JAVELIN [45] | Avelumab | 2 | TRAEs: Acute liver failure (n = 1), respiratory distress (n = 1) |
| | | | No patients died due to IRAEs |

*Atezo* atezolizumab; *Coh* cohort; *CT* chemotherapy; *DIC* disseminated intravascular coagulation; *Durva* durvalumab; *MI* myocardial infarction; *MODS* multiple organ dysfunction syndrome; *n* number; *NR* not reported; *Pembro* pembrolizumab; *TRAEs* treatment-related adverse events
occurs due to study therapy. In a retrospective study, anti-PD-1 therapy was given after a severe ipilimumab-related adverse event requiring immunosuppression in patients with melanoma. Subsequent anti-PD-1 therapy resulted in a low rate of IRAE recurrence (3%), suggesting that treatment with another immunotherapy agent may be a suitable retreatment approach. Nevertheless, new IRAEs occurred frequently (34%), and many of these were high grade (21% grade 3–4) [58]. Another retrospective study explored patients with non-small cell lung cancer treated with anti–PD-1 or anti–PD-L1 therapy who experienced IRAEs requiring ICI treatment delay, treatment with glucocorticoids, or both, and who were later retreated with anti–PD-1 or anti–PD-L1 therapy. Among 39 patients who were retreated, 50% had no further IRAEs, 26% had a recurrence of the initial event, and 23% had a new event [59]. Dolladille et al. evaluated the rate of IRAE recurrence after the resumption of ICI therapy in patients with cancer. A total of 24,079 IRAEs associated with at least one ICI were identified from a database. The recurrence rate of the same IRAE was 28.8%, while a different IRAE occurred in 4.4% of patients. This study showed that colitis, pneumonitis and hepatitis were associated with a higher recurrence rate, whereas adrenal events were associated with a lower recurrence rate [60]. These results suggest that restarting ICB therapy after the resolution of IRAEs may lead to recurrent or new IRAEs. Resuming ICI therapy could be considered for select patients with appropriate monitoring and the use of standard treatment algorithms to identify and treat adverse events [60].

When restarting ICB treatment, clinicians must consider the severity of the prior event, the availability of alternative treatment options, and the overall status of the cancer. Retreatment with ICB is contraindicated if there is a life-threatening toxicity, particularly cardiac, pulmonary, or neurologic toxicity [1, 61]. The type of toxicity is also an important consideration in making retreatment decisions.

In cases of thyroid, adrenal and pituitary disorders, for instance, patients can be retreated with ICI after hormone repletion and resolution of acute symptoms. Given the complexity of retreatment decisions, referral to multidisciplinary boards, including oncologists, internal medicine specialists, and organ specialists, is necessary. Recommendations for retreatment with ICIs after the occurrence of IRAEs are summarized in Table 5.

**Conclusion**

ICI therapy has demonstrated improving outcomes in patients with TNBC, particularly in the metastatic setting. However, with the increased use of ICIs in patients with breast cancer, clinicians have observed common and also rare IRAEs. Therefore, having an awareness of these toxicities, which differ from classical chemotherapy-related toxicities, can help lead to early recognition and optimal management. To educate patients about IRAEs and to establish physician knowledge of successful IRAE treatment strategies are important in preventing complications from potentially life-threatening IRAEs. Ongoing studies in patients with breast cancer are needed to understand the mechanisms and management of IRAEs and to prevent significant morbidity and potential mortality secondary to these agents.

---

**Table 5** Recommendations for retreatment with ICIs after IRAE occurrence

| Toxicity          | Cautiously retreat                                      | Permanently discontinue                                   |
|-------------------|---------------------------------------------------------|----------------------------------------------------------|
| Endocrine         | Hormone repletion and resolution of acute symptoms      | Symptomatic pituitary inflammation                        |
| Dermatologic      | Grade ≤ 1 rash or pruritus                              | Grade 4, Grade 3–4 bullous dermatitis, SJS/TEN             |
| Hepatitis         | Grade ≤ 2 transaminits, bilirubin < ULN, steroid < 10 mg/d | Grade 3–4 hepatitis                                       |
| Colitis           | Grade 2–3 colitis, steroid < 10 mg/d                    | Grade 4 colitis                                           |
| Pneumonitis       | Grade 1–2, steroids discontinued                        | Grade 3–4 pneumonitis, no improvement after 48–72 h of steroids |
| Neurologic        | Grade 1–2 peripheral neuropathy                         | Guillain-Barre Syndrome, moderate/severe encephalitis, transverse myelitis, Grade 2–4 myasthenia gravis, |
| Cardiovascular    | Grade ≤ 1 myocarditis                                   | Grade 2–4 myocarditis, pericarditis                       |
| Rheumatologic     | Stabilization after adequate supportive care            | Severe inflammatory arthritis that impairs ADLs           |
| Renal             | Grade 1–2, steroid < 10 mg/d                            | Grade 3–4 proteinuria                                     |
| Ocular            | Grade ≤ 2                                              | Grade 3–4 uveitis or episcleritis                          |

ADLs activities of daily living; d day; ICI immune checkpoint inhibitor; IRAEs immune-related adverse events

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
permited by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168
2. Nanda R et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34(21):2460
3. Herbst RS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567
4. Schmid P et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121
5. Cortes J et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828
6. Schmid P et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821
7. Mittendorf EA et al (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090–1100
8. Puzanov I et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):1–28
9. Abdel-Rahman O, ElHalawani H, Fouad M (2016) Risk of endocrine complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 12(3):413–425
10. Naidoo J et al (2017) Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35(7):709
11. Caturegli P et al (2016) Hypophysitis secondary to cytotoxic T-lymphocyte–associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186(12):3225–3235
12. Osorio J et al (2016) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589
13. Michot J et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148
14. Callahan M et al (2011) Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol 29(15_suppl):2505–2505
15. Dubin K et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7(1):1–8
16. Ramos-Casals M et al (2020) Immune-related adverse events of metastatic triple-negative breast cancer: safety first? Nat Rev Clin Oncol 16(7):399–400
17. Arnaud-Coffin P et al (2019) A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 145(3):639–648
18. D’Abreo N, Adams S (2019) Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first? Nat Rev Clin Oncol 16(7):399–400
19. Patrinely JR et al (2021) Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma. JAMA Oncol 7(4):744
20. National Cancer Institute (2019) Common terminology criteria for adverse events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 8 June 2021
21. Barroso-Sousa R et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173–182
22. Thompson JA (2018) New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Nat Compr Cancer Netw 16:594–596
23. Byun DJ et al (2017) Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207
24. Martins F et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580
25. Emens LA et al (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5(1):74–82
26. Schmid P et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59
27. Torino F, Corsello SM, Salvadori R (2016) Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28(4):278–287
28. Fajie A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92
29. Nanda R et al (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6(5):676–684
30. BLA 125514 Supplement-089. Drug name: Pembrolizumab (2021) F.I.C.F.a.A.O.B.D.R.F.. 2021, from https://www.fda.gov/media/145654/download. Accessed 8 June 2021
31. Adams S et al (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30(3):397–404
32. Kumar V et al (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49
33. Belum V et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12–25
34. Curry JL et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176
35. Larkin J et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34
36. Gonzalez RS et al (2017) PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis.’ Histopathology 70(4):558–567
37. Miles D, Glisovic J, André F et al (2021) Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:994–1004
38. Adams S et al (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30(3):405–411
39. Cramer P, Bresalier RS (2017) Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19(1):3
40. Jun J et al (2019) Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: three case reports and literature review. Medicine 98(25):e16158
41. Cuzzubbo S et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8
42. Loibl S et al (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30(8):1279–1288
43. Touat M et al (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659–668
44. Guglin M, Nallamshetty L (2012) Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med 14(6):637–651
45. Kindermann I et al (2012) Update on myocarditis. J Am Coll Cardiol 59(9):779–792
46. Cooper LT et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50(19):1914–1931
47. Winer EP et al (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22(4):499–511
48. Dirix LY et al (2018) Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 167(3):671–686
49. Cappelli LC et al (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 69(11):1751–1763
50. Wanchoo R et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45(2):160–169
51. Cortazar FB et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638–647
52. Emens LA et al (2019) Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis. JAMA Ophthalmol 137(1):96–100
53. Kennedy LB, Salama AK (2020) A review of cancer immunotherapy toxicity. CA: Cancer J Clin 70(2):86–104
54. Beattie J et al (2020) Success and failure of additional immunosuppressants in steroid-refractory pneumonitis related to immune checkpoint blockade. Am Soc Clin Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.3078
55. Wang DY et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728
56. Santini FC et al (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD (L)-1 therapy. Am Soc Clin Oncol 35(15_suppl):9012
57. Dolladille C et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6(6):865–871
58. Simonaggio A et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310–1317

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.